Navigation Links
Japan Pharmaceutical Market Outlook
Date:8/15/2013

DUBLIN, August 15, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/m8z7c3/japan) has announced the addition of the "Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

GBI Research, the leading business intelligence provider, has released its latest research Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players. Japan's pharmaceutical industry is the second largest in the world, worth $89 billion in 2011 or 10% of the world market. The industry grew from $62.8 billion in 2005 to its current value at a Compound Annual Growth Rate (CAGR) of 5.1%.

Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. Price reviews are also constrained by a national health budget, which limits the increase of drug prices. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use.

However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing market share of generics may dampen market value, this represents a great deal of opportunity for generic manufacturers.

Historically, the Japanese pharmaceutical market has favored domestic companies. However, since the 1990s, deregulation has promoted investment from abroad and increased the presence of foreign firms.

Scope

- The report assesses characteristics of the Japanese pharmaceutical market, detailing recent regulatory changes, supply chain and competitive
landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy.

- A macroeconomic analysis of Japan, focusing on key economic parameters such as Gross Domestic Product (GDP), inflation and unemployment. The implications of the global financial crisis in 2008 and natural disaster in 2011 are considered.

- The changing demographic landscape and implications on health economics and policy-making.

- The industry characteristics section presents an overview of pricing policies, the regulatory landscape, new drug approval process and pharmaceutical supply chain in Japan. Notable changes that have occurred over recent years, in an attempt to improve the regulatory system and reduce drug review times, are highlighted.

- The report then analyzes the competitive landscape in Japan, including the major domestic companies and M&A. The discussed regulatory reforms and cooperation between government and industry have improved the international competitiveness of Japan's pharmaceutical market. Coupled with a number of mergers, the industry now consists of well-known multinationals. The competitive landscape section confirms the top five Japanese pharmaceutical companies by revenue, according to GBI Research data.

- The report concludes by providing an overview of the drivers and barriers currently facing the Japanese pharmaceutical industry.

Companies Mentioned

- Astellas Pharma Inc.
- Daiichi Sankyo Ltd.
- Eisia Ltd.
- Otsuka Holdings Ltd.
- Takeda Pharmaceutical Ltd.

For more information visit http://www.researchandmarkets.com/research/m8z7c3/japan

About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals



'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Empire Genomics Chooses Funakoshi as Japan Distributor
2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
3. Accuray Rolls Out Comprehensive Customer Service Program in Japan
4. CPhI Japan Triumphs in the Prestigious AEO Excellence Awards
5. Japanese Market for Orthopedic Soft Tissue Repair & Sports Medicine
6. Pharmaceutical Supply Chain in Japan - Periodic Drug Price Revisions by National Health Insurance Increase Competition and Squeeze Profit Margins
7. Pfizer and Mylan Team Up to Establish Exclusive Long-Term Strategic Collaboration to Drive Sustained Growth of Generics Business in Japan
8. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
9. Japan Pharma Review: Outlook to 2017
10. The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 JCA-Mauvernay Award for their Innovative and Outstanding Cancer Research
11. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June ... -based mobile pulmonary function testing company, is now able to ... devices developed by ndd Medical Technologies , Inc. ... done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ... , can get any needed testing done in the comfort of ...
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):